High dose pharmacy-grade biotin is under evaluation for the treatment of adrenomyeloneuropathy. Biotin is also known as Vitamin H or Vitamin B7. This treatment could lead to a clinical improvement in walking of patients who are affected by the condition. In the phase III clinical trial, biotin is administered orally at 100mg three times a day for twenty-four months. Current treatments are limited to those which address symptoms of the condition and active physical rehabilitation.